COMMUNIQUÉS West-GlobeNewswire

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
19/02/2026
Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when [...]
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
19/02/2026
Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a company focused on [...]
Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina
19/02/2026
Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, Nasdaq: [...]
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
19/02/2026
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
19/02/2026
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally [...]
Sienna Reports Fourth Quarter 2025 Financial Results and Continues Platform Growth
19/02/2026
MARKHAM, Ontario, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and twelve months ended December 31, 2025. [...]
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
19/02/2026
RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate cancer [...]
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
19/02/2026
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD [...]
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
19/02/2026
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for [...]
Candel Therapeutics Announces Proposed $100 Million Public Offering
19/02/2026
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Curaechoice and The Center for Pain to Deliver No-Cost Pain Management to Members Nationwide
19/02/2026
Curaechoice Members and Their Families Now Have Access to Comprehensive Pain Management Services from The Center for Pain, a Clearway Company, at $0 Cost. Birmingham, ALABAMA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
19/02/2026
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA [...]
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
19/02/2026
Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune [...]
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
19/02/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share [...]
Human Appeal reaches over 862,000 people with food, water and life-saving emergency response amid ongoing Sudan conflict
19/02/2026
The humanitarian charity has made efforts to provide food parcels, hot school meals and assist with clean water supply across Sudan during the ongoing conflict which is driving mass displacement MISSION VIEJO, Calif., [...]
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
19/02/2026
NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable [...]
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
19/02/2026
Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma Plc (“Herantis”), a [...]
Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan
19/02/2026
MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Klothea Bio, Inc. (“Klothea Bio”), a clinical-stage biotechnology company developing therapeutics based on their proprietary serum klotho platform, today announced the launch of [...]
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
19/02/2026
Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab [...]

Pages